Target Details
| UniProt AC | P48775 |
|---|---|
| Gene Symbol | TDO2 |
| Protein Name | Tryptophan 2,3-dioxygenase |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF03301 (Trp_dioxygenase) |
Summary
- Multi-target molecules 240
- Clinical molecules 0
- Avg pChEMBL 6.59
KEGG Pathways (3)
Associated Diseases (1)
Active Molecules (240)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
XOIBIBZONGFJRB
|
6.2 | IC50 | 2 | — | |
CXWRSQDVQMEABQ
|
6.2 | IC50 | 2 | — | |
GPFCJWJSFAPBNK
|
6.2 | IC50 | 2 | — | |
JJPOOSLOAJIUFW
|
6.2 | IC50 | 2 | — | |
WKDBQKZUIUUMLE
|
6.2 | IC50 | 2 | — | |
AEMVYCHLYDWVGY
|
6.2 | IC50 | 2 | — | |
FHLMOHXPRRSHRY
|
6.2 | IC50 | 2 | — | |
JUXORWMABIQBQK
|
6.2 | IC50 | 2 | — | |
WOALNEUXJJGUMC
|
6.2 | IC50 | 2 | — | |
WUQOZYPTLRTOED
|
6.2 | IC50 | 2 | — | |
FUGHJGNJPYRQFX
|
6.2 | IC50 | 2 | — | |
HNMLFYAVNXUMDX
|
6.2 | IC50 | 2 | — | |
YPWFUCJPQCIMOV
|
6.2 | IC50 | 2 | — | |
QUDANWQDAHSKPJ
|
6.2 | IC50 | 2 | — | |
YOTSKOBPSGTBDN
|
6.2 | IC50 | 2 | — | |
OJBKRVHPGUIOAM
|
6.2 | IC50 | 2 | — | |
RVSUFTQTIGUXBU
|
6.2 | IC50 | 2 | — | |
VZSQBPCMUNWVCP
|
6.2 | IC50 | 2 | — | |
PVVXYQFKBXRDSW
|
6.2 | IC50 | 2 | — | |
AZXIIVGCMUUVTL
|
6.1 | IC50 | 2 | — | |
CICLBCJHLAGMIY
|
6.1 | IC50 | 2 | — | |
OGJIUQZGECSYFP
|
6.1 | IC50 | 2 | — | |
UUSLIOFTAIOJSB
|
6.1 | IC50 | 2 | — | |
AQVLIGKLPHQUOG
|
6.1 | IC50 | 2 | — | |
GILHXZMMODSEGS
|
6.1 | IC50 | 2 | — | |
ZDRWYPMDHVEHIG
|
6.1 | IC50 | 2 | — | |
IBWLZSJWENDWOJ
|
6.1 | IC50 | 2 | — | |
KHONZILMMZKIQL
|
6.1 | IC50 | 2 | — | |
LQPZZJZECDWKCW
|
6.1 | IC50 | 2 | — | |
NRSXRBWOTJJSBQ
|
6.1 | IC50 | 2 | — | |
KXWJQTZVXMANSZ
|
6.0 | IC50 | 2 | — | |
VSNYUPBGAQQVCB
|
6.0 | IC50 | 2 | — | |
CCUBFPOONNDKHL
|
6.0 | IC50 | 2 | — | |
MGMLZAGUHKYFRS
|
6.0 | IC50 | 2 | — | |
OFZXVDIQPLYNJJ
|
6.0 | IC50 | 2 | — | |
QTUSOWIRENUFCA
|
6.0 | IC50 | 2 | — | |
FPKOOQWQTIMSGB
|
6.0 | IC50 | 2 | — | |
HUXJWSCWWJDQNA
|
6.0 | IC50 | 2 | — | |
KQBLDQUVTHHHOZ
|
6.0 | IC50 | 2 | — | |
NUOMVFPVKSHIDX
|
6.0 | IC50 | 2 | — |